Type 2 diabetes. E11
Conditions
Interventions
Intervention 1: Intervention group: Group A =Intervention in normal weight diabetes patients by reducing 500kcal of daily energy requirement for 12 months. Intervention 2: Intervention group: Group B
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Criteria for inclusion in the study: normal and overweight patients with type 2 diabetes Aged between 18 to 65 Consumption of same drugs (glibenclamide, metformin)
Exclusion criteria
Exclusion criteria: Criteria for exclusion from the study: Suffering from liver diseases Suffering from thyroid disease Pregnancy and lactation Smoking and drinking alcohol Consumption of drugs reducing blood fat and pressure and Weight, thiazide diuretics and corticosteroids Change of type and dosage of consuming drugs during the study Consumption of Herbal or chemical supplements Suffering from Digestive diseases associated with malabsorption Gastric bypass surgery and cholecystectomy Insulin Therapy people who have been on weight loss diet or had been treated with drugs and supplements related to weight loss (such as Orlistat or Slim Last dietary supplements) in the past three months Suffering from diabetic complications such as nephropathy, retinopathy, neuropathy and cardiovascular complications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insulin resistance. Timepoint: At weeks 0, 12. Method of measurement: (fasting serum glucose (mmol/L) × fasting serum insulin (µIU/ml))/22.5.;Quantitative Insulin Sensitivity Check Index. Timepoint: At weeks 0, 12. Method of measurement: 1/ [ log(fasting insulin, µU/ml) + log (fasting glucose, mg/dl) ].;Fasting Blood Sugar. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg/dl.;Serum insulin. Timepoint: At weeks 0, 12. Method of measurement: Radioimmunoassay.;Systolic blood pressure. Timepoint: At weeks 0, 12. Method of measurement: Mercury pressure gauge, Mm mercury.;Diastolic blood pressure. Timepoint: At weeks 0, 12. Method of measurement: Mercury pressure gauge, Mm mercury.;Body composition analysis (Weight, Body mass index, Fat mass, Fat free mass, Visceral fat area, Waist circle, Waist to hip ratio, Skeletal muscle mass). Timepoint: At weeks 0, 12. Method of measurement: Inbody770 Body Analyzer, Bioelectrical impedance analysis.;HbA1c. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, %.;Lipid profile (Triglyceride,Total cholesterol, VLDL, LDL, HDL?). Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg / dl.;Liver enzymes (ALP, ALT, AST). Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, IU/L. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMajid Monafi
Oroumia University of Medical Sciences
Outcome results
None listed